As printed in BioCentury, The Bernstein Report on BioBusiness 9 August 2010 by Aaron Bouchie

aTyr's fresh biology 

aTyr Pharma Inc. is developing therapies based on physiocrines, a new class of proteins that could play roles in inflammation, autoimmune and metabolic diseases, and blood disorders. Because physiocrines are involved in newly discovered biological pathways, the company expects some to be druggable targets themselves and some to be developed as therapeutics targeting both new and known receptors.

As printed in South China Morning Post 7 November 2009 by Maggie Ng

Newly discovered proteins could aid disease treatments

November 7, 2009 -A visiting professor at the Hong Kong University of Science and Technology has discovered three proteins that could be effective for new therapeutics for diabetes, tumors and blood-related diseases.

ATyr Heads for Clinic with First of Many Synthetase Fragments

April 27, 2009 - What began when serial entrepreneur Paul Schimmel founded Angiosyn Inc. - later sold to Pfizer Inc. for $527 million - is advancing to the next level in the hands of San Diego start-up aTyr Pharma Inc.